Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 19 | 2023 | 151 | 5.560 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2023 | 170 | 3.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 878 | 2.260 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2023 | 35 | 1.820 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 261 | 1.400 |
Why?
|
| Antigens, CD19 | 10 | 2023 | 39 | 1.380 |
Why?
|
| Lymphoma, B-Cell | 5 | 2022 | 103 | 1.300 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 331 | 1.070 |
Why?
|
| Oncologists | 1 | 2023 | 36 | 0.920 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 18 | 0.780 |
Why?
|
| Blood Component Removal | 1 | 2020 | 24 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 120 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 189 | 0.750 |
Why?
|
| Biological Products | 4 | 2023 | 143 | 0.740 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 373 | 0.730 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 1313 | 0.700 |
Why?
|
| Lymphoma | 2 | 2018 | 262 | 0.690 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2023 | 372 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2438 | 0.570 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 78 | 0.550 |
Why?
|
| Lymphoma, Follicular | 3 | 2022 | 70 | 0.540 |
Why?
|
| Humans | 46 | 2023 | 86643 | 0.530 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 365 | 0.500 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 43 | 0.490 |
Why?
|
| Hepatitis B | 1 | 2014 | 74 | 0.470 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 724 | 0.450 |
Why?
|
| Retrospective Studies | 9 | 2023 | 8489 | 0.420 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1384 | 0.420 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 136 | 0.410 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 185 | 0.370 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2023 | 49 | 0.360 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2360 | 0.340 |
Why?
|
| Prognosis | 3 | 2023 | 3679 | 0.320 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1195 | 0.290 |
Why?
|
| Sarcopenia | 2 | 2016 | 13 | 0.280 |
Why?
|
| Aged | 13 | 2023 | 18415 | 0.270 |
Why?
|
| Adult | 12 | 2023 | 25648 | 0.250 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.240 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2023 | 9 | 0.240 |
Why?
|
| Candidiasis | 1 | 2023 | 36 | 0.230 |
Why?
|
| Survival Analysis | 3 | 2023 | 1538 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 138 | 0.220 |
Why?
|
| Veterans | 4 | 2016 | 72 | 0.210 |
Why?
|
| Rituximab | 4 | 2016 | 116 | 0.210 |
Why?
|
| Tumor Burden | 1 | 2023 | 289 | 0.210 |
Why?
|
| Middle Aged | 11 | 2022 | 25028 | 0.210 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 177 | 0.210 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 166 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 183 | 0.200 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 112 | 0.200 |
Why?
|
| United States | 7 | 2023 | 6672 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 930 | 0.190 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 559 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 44 | 0.180 |
Why?
|
| Carcinoma | 1 | 2023 | 436 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 329 | 0.170 |
Why?
|
| Male | 13 | 2023 | 40965 | 0.170 |
Why?
|
| Patient Selection | 2 | 2019 | 685 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Neoplasms | 2 | 2023 | 2898 | 0.160 |
Why?
|
| Female | 12 | 2023 | 44532 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 397 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 81 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 265 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 307 | 0.150 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 299 | 0.140 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 8 | 0.140 |
Why?
|
| Remission Induction | 3 | 2023 | 722 | 0.140 |
Why?
|
| Body Composition | 1 | 2016 | 68 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 712 | 0.140 |
Why?
|
| Recurrence | 3 | 2023 | 1139 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 270 | 0.130 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 183 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2015 | 37 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Doxorubicin | 4 | 2016 | 295 | 0.130 |
Why?
|
| Survivors | 1 | 2016 | 226 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 14 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 153 | 0.120 |
Why?
|
| Heart Failure | 1 | 2023 | 1204 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 763 | 0.120 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 996 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1197 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1169 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2023 | 76 | 0.110 |
Why?
|
| Time Factors | 1 | 2021 | 5210 | 0.110 |
Why?
|
| Adolescent | 2 | 2023 | 8981 | 0.110 |
Why?
|
| Vincristine | 3 | 2016 | 111 | 0.100 |
Why?
|
| Prednisone | 3 | 2016 | 258 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 770 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 510 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2021 | 839 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1376 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 4213 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6509 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 66 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 239 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 107 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2023 | 220 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 24 | 0.060 |
Why?
|
| Cattle | 1 | 2023 | 376 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2023 | 273 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.060 |
Why?
|
| Outpatients | 1 | 2023 | 94 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 140 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 190 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 250 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 300 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1577 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 151 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7993 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.050 |
Why?
|
| Filgrastim | 1 | 2019 | 56 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.050 |
Why?
|
| Hydrazines | 1 | 2019 | 30 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11352 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 96 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 218 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 79 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 26582 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 592 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 463 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 177 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1718 | 0.040 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 18 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 215 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2767 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 114 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 859 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 449 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3092 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1019 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1036 | 0.030 |
Why?
|
| Mutation | 1 | 2022 | 3968 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 849 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5976 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2601 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3362 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5417 | 0.020 |
Why?
|